To Join the NPIN community Sign In or Join
Want to improve your HIV program? Don’t reinvent the wheel another HIV prevention professional already created. Join NPIN’s new social community to connect, share, and collaborate.
Where to go for the ABCs of viral hepatitis prevention? Join other professionals on NPIN’s new social community to connect, share, and collaborate.
Talk sexual health services with other STD prevention professionals. Join NPIN’s new social community to connect, share, and collaborate.
Looking for a place to discuss TB best practices, resources, and challenges? Connect, share, and collaborate with other prevention professionals.
The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available over the past few years. To provide healthcare professionals with timely guidance as new therapies become available and are integrated into HCV regimens, the Infectious Diseases Society of America (IDSA) and American Association for the Study of Liver Diseases (AASLD), developed a web-based process for the rapid formulation and dissemination of evidence-based, expert-developed recommendations for hepatitis C management.
